CN103929980A - 含有高sn-2棕榈酸酯和低聚果糖的婴儿配方乳 - Google Patents
含有高sn-2棕榈酸酯和低聚果糖的婴儿配方乳 Download PDFInfo
- Publication number
- CN103929980A CN103929980A CN201280055439.3A CN201280055439A CN103929980A CN 103929980 A CN103929980 A CN 103929980A CN 201280055439 A CN201280055439 A CN 201280055439A CN 103929980 A CN103929980 A CN 103929980A
- Authority
- CN
- China
- Prior art keywords
- infant formula
- approximately
- milk
- fat
- 100kcal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 87
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 title description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 79
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 34
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000344 soap Substances 0.000 claims abstract description 32
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011575 calcium Substances 0.000 claims abstract description 10
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 9
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 9
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 9
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 9
- 210000001072 colon Anatomy 0.000 claims abstract description 6
- 210000004080 milk Anatomy 0.000 claims description 87
- 235000013336 milk Nutrition 0.000 claims description 86
- 239000008267 milk Substances 0.000 claims description 80
- 239000002253 acid Substances 0.000 claims description 35
- 125000001931 aliphatic group Chemical group 0.000 claims description 31
- 239000002689 soil Substances 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 15
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 210000003608 fece Anatomy 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 3
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 235000020256 human milk Nutrition 0.000 abstract description 7
- 210000004251 human milk Anatomy 0.000 abstract description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 abstract 1
- 229940033080 omega-6 fatty acid Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 29
- 210000000481 breast Anatomy 0.000 description 17
- 235000019197 fats Nutrition 0.000 description 17
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 235000020778 linoleic acid Nutrition 0.000 description 9
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 description 8
- 239000008158 vegetable oil Substances 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 6
- 239000011707 mineral Substances 0.000 description 6
- 235000010755 mineral Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 150000004671 saturated fatty acids Chemical class 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000024188 Andala Species 0.000 description 3
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical group O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- -1 palmitate triglycerides Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 125000005457 triglyceride group Chemical group 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 244000188595 Brassica sinapistrum Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 240000005481 Salvia hispanica Species 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000016693 dipotassium tartrate Nutrition 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 150000002759 monoacylglycerols Chemical class 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
- A23C9/203—Dietetic milk products not covered by groups A23C9/12 - A23C9/18 containing bifidus-active substances, e.g. lactulose; containing oligosaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Edible Oils And Fats (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及含有相对高含量具有位于sn-2位的棕榈酸的甘油三酯的婴儿配方乳。所述配方乳可包含低聚果糖。所述配方乳还可包含至少一种ω-6脂肪酸和至少一种ω-3脂肪酸。所述配方乳还可含有与人乳类似的相对低的蛋白质含量和α-乳清蛋白含量。本发明还包括用于改善配方乳喂养的婴儿的粪便稠度、增加结肠中双歧杆菌、减少结肠中潜在的病原菌和减少粪便中钙皂的方法。
Description
发明背景
本发明涉及含有高sn-2棕榈酸酯甘油三酯和低聚果糖的婴儿配方乳(infant formula)组合物。
甘油三酯由含有三个羟基的甘油和三分子脂肪酸通过酯键形成。甘油三酯在新陈代谢中作为能量源而起重要作用。肠道中,在称作脂解的过程中,甘油三酯裂解成单酰基甘油和游离脂肪酸,其中游离脂肪酸分离自甘油三酯的sn-1和sn-3位。不饱和游离脂肪酸比饱和脂肪酸明显更容易被肠道吸收。当甘油三酯的sn-1和/或sn-3位包含高百分比的饱和脂肪酸残基时,脂解形成的游离脂肪酸(例如棕榈酸)可与矿物质例如钙或镁结合,形成皂(soaps),其使粪便变得更硬,更难以通过。所述皂的形成还可干扰钙吸收。
人乳脂甘油三酯含有大约20-25%的棕榈酸残基,所述残基大约70%的存在于它们所键合的甘油酯的sn-2位。通常将植物油代替乳脂用于婴儿配方乳中。植物油甘油三酯通常含有高百分比(典型地为80-85%或者更多)的存在于sn-1或sn-3位的棕榈酸。因此,人乳消化期间形成的游离脂肪酸主要是不饱和脂肪酸,而植物油消化期间释放的脂肪酸大多是饱和脂肪酸,其可以与钙结合形成皂。这可解释为什么已知母乳喂养的婴儿比配方乳喂养的婴儿具有更软的粪便。
重要的ω-6脂肪酸亚油酸(LA)和重要的ω-3脂肪酸α亚麻酸(ALA)是人类正常生长和发育所必需的。LA和ALA脂肪酸在代谢方面是不同的,不能在人体中合成,且必须从哺乳动物的膳食中获得。在进化史中,对于LA和ALA的摄取,在人的膳食中存在大体平衡(general balance),且LA与ALA的比率是约1:约1。尤其在西方社会,由于现代农业方法学和运输的便捷,高LA的植物油(玉米油、葵花油、红花油、大豆油)消费增加,急剧地使一些哺乳动物膳食中的哺乳动物摄取的LA:ALA的比率从大约1:1移至大约10-25LA:约1ALA。
需要这样的婴儿配方乳,其中甘油三酯含有比植物油存在的更多的sn-2棕榈酸酯,以及更少的sn-1和sn-3棕榈酸酯。
在婴儿制品(infant formulation)中,利用β棕榈酸酯脂肪优化脂肪混合物,以提高钙堆积(accretion)和降低粪便皂脂肪酸是合乎需要的。并且,包含约6:约1比率的至少一种ω-6脂肪酸和至少一种ω-3脂肪酸将提供短期和长期的健康益处,包括改善的二十二碳六烯酸(“DHA”)的生物利用度。
具有所述特征的多种植物来源的甘油三酯在本领域是已知的。
EP1237419描述包含甘油的sn-1和sn-3位不含大量饱和脂肪酸的易消化脂质组分、粘性改善成分、含有低于0.75g磷/100g蛋白质的蛋白组分和/或益生元组分例如寡糖的婴儿配方乳。
WO2005/036987描述新的基于脂肪的制品,其包含含有至多38%棕榈酸残基的植物来源的甘油三酯的混合物,其中至少60%的棕榈酸残基在甘油酯的sn-2位,优选至少70%的不饱和脂肪酸残基例如油酸酯占据sn-1和sn-3位。
WO2006/114791描述用作婴儿配方乳的人乳脂替代品,其含有植物来源的甘油三酯,sn-2位的少于50%的脂肪酸残基是饱和的和/或sn-2位的饱和脂肪酸残基低于总包含脂肪酸残基的43.5%。
低聚果糖是由相对低度聚合的果糖单位构成的寡糖。低聚果糖在本领域是众所周知的且是市售的。
美国专利号7,651,716描述含有2.2-2.5g/Lα-乳清蛋白(大约0.3-0.4g/100kcal)的婴儿配方乳,且其似于人乳。还公开婴儿配方乳的2.0-2.4g/100kcal的总蛋白含量。
美国专利号5,658,768、WO2007/029015、WO2007/029018、WO2007/029020和WO2008/104381描述了用于生产甘油三酯组合物的方法,所述甘油三酯组合物在sn-2位具有相对高百分比的饱和脂肪残基例如棕榈酸。Lipid Nutrition出售的市售组合物是BetapolTMB-55,其是植物油来源的甘油三酯混合物,其中至少54%的棕榈酸位于甘油分子的sn-2位。
发明简述
本发明包括每100kcal婴儿配方乳包含下述成分的婴儿配方乳:
a)大概约5g至约6g的脂肪,其中总脂肪的至少7.5重量%由包含位于sn-2位的棕榈酸的甘油三酯构成;
b)任选地,至少约0.4g低聚果糖;和
c)大概约1.8g至约2.2g的总蛋白,任选地包括大概约0.3g至约0.4g的α-乳清蛋白。
本发明包括每100kcal婴儿配方乳含有下述成分的婴儿配方乳:
a)约5-6g的脂肪,其中总脂肪的至少7.5重量%由包含位于sn-2位的棕榈酸的甘油三酯构成;
b)任选地,至少约0.4g低聚果糖;
c)大概约1.8g至约2.2g的总蛋白,任选地包括大概约0.3g至约0.4g的α-乳清蛋白;和
d)约6:约1比率的至少一种ω-6脂肪酸和至少一种ω-3脂肪酸。
本发明还包括用于改善婴儿粪便稠度的方法,其包含向所述婴儿施用本发明的婴儿配方乳。
本发明还包括用于降低婴儿粪便中钙皂(calcium soaps)的量的方法,所述方法包含向所述婴儿施用本发明的婴儿配方乳。
本发明还包括用于增加婴儿结肠中有益双歧杆菌的量的方法。
根据下文描述,本发明的其他重要方面将是显而易见的。
附图简述
图1是显示各种婴儿配方乳和人乳喂养的婴儿粪便双歧杆菌变化的棒图。
图2是显示各种婴儿配方乳和人乳喂养的婴儿粪便稠度的棒图。
图3是显示各种婴儿配方乳和人乳喂养的婴儿粪便中棕榈酸皂的量的棒图。
发明详述
文中所用的术语“低聚果糖”指具有2-10的聚合度例如2-8的聚合度的果糖低聚体。
文中所用的术语“sn-2棕榈酸酯”涉及在其所键合的甘油三酯的sn-2位的棕榈酸。
文中所用的术语“婴儿配方乳”指营养制品(nutritionalformulation)(液体形式的,或者一旦加入水可重构而形成液体婴儿配方乳的干燥粉末形式的),其为婴儿提供完全营养,并适合于喂养婴儿,且其符合婴儿配方乳的US或EU标准。所述配方乳在本领域是众所周知的。
典型地,即刻食用的(ready-to-consume)液体形式的婴儿配方乳提供60-70kcal/100ml。婴儿配方乳每100Kcal典型地包含:约1.8-4.5g蛋白质;约3.3-6.0g脂肪(脂质);约300-1200mg亚油酸;约9-14g碳水化合物,其选自乳糖、蔗糖、葡萄糖、葡萄糖浆、淀粉、麦芽糊精和麦芽糖,及其组合;以及必需维生素和矿物质。乳糖可以是婴儿配方乳中主要的碳水化合物。例如液体婴儿配方乳可含有约67kcal/100ml。在一些实施方案中,婴儿配方乳可含有约1.8-3.3g蛋白质/100Kcal。婴儿配方乳可以是粉末形式的,其可通过加入一定量的水(导致产生含有约67kcal/100ml的液体)而重构成即食液体。
婴儿配方乳还可含有核苷酸,其选自胞苷5'-一磷酸(CMP)、尿苷5'-一磷酸(UMP)、腺苷5'-一磷酸(AMP)、鸟苷5'-一磷酸(GMP)和肌苷5'-一磷酸(IMP)及其混合物。婴儿配方乳还可含有叶黄素、玉米黄素、果糖-寡聚体、半乳糖-寡聚体、唾液酰-乳糖和/或岩藻糖基-乳糖。长链多不饱和脂肪酸例如二十二碳六烯酸(DHA)和花生四烯酸(AA)可包括于婴儿配方乳中。婴儿配方乳还可包含游离氨基酸。婴儿配方乳还可包含本领域众所周知的其他成分。
在一实施方案中,本发明的婴儿配方乳包含约5-6g脂肪(甘油三酯)/100kcal,至少约7.5wt%例如约7.5-12.0%的所述脂肪具有位于甘油三酯sn-2位的棕榈酸。在一些实施方案中,约7.8-11.8%、约8.0-11.5wt%、约8.5-11.0%或者约9.0-10.0wt%的脂肪是位于甘油三酯sn-2位的棕榈酸。
在一些实施方案中,棕榈酸占配方乳脂肪酸总含量的约15重量%至约25重量%,例如约15重量%至约20重量%,并且棕榈酸总含量的至少约30%例如约35%至约43%位于sn-2位。
在一些实施方案中,婴儿配方乳还以约6:约1的比率含有至少一种ω-6脂肪酸和至少一种ω-3脂肪酸。在一实施方案中,至少一种ω-6脂肪酸占脂肪酸总重量的约10%至约15%,且至少一种ω-3脂肪酸占总脂肪酸的约1.2%至约3.6%。在一些实施方案中,婴儿配方乳包含总重量的约2%至约4%的至少一种ω-6脂肪酸,和总重量的约0.3%至约0.6%的至少一种ω-3脂肪酸。
本发明婴儿配方乳中的脂肪包括通常发现于奶和/或婴儿配方乳中的多种甘油三酯。甘油三酯中最常见的脂肪酸残基是棕榈酸和油酸。除油酸和棕榈酸之外,存在的脂肪酸残基包括但不限于亚油酸、α亚麻酸、月桂酸、肉豆蔻酸、二十二碳六烯酸和花生四烯酸。
Lipid Nutrition出售的市售组合物是BetapolTMB-55,其是来自植物油的甘油三酯混合物,其中至少54%的棕榈酸位于甘油分子的sn-2位。在一实施方案中,本发明配方乳的脂肪含量是约40重量%-50重量%BetapolTMB-55,例如约43重量%至约45重量%。本领域的技术人员应理解在不背离本发明精神和范围的情况下,配方乳中所用的高sn-2脂肪的百分比和sn-2棕榈酸酯的总量可变化,并且可使用不同的高sn-2棕榈酸酯油。
虽然给婴儿喂食含有高百分比sn-2棕榈酸酯的配方乳有助于产生较软的粪便,并有助于结肠中双歧杆菌的生长,但是高sn-2棕榈酸酯与低聚果糖的组合提供明显更优的粪便软化和配方乳喂养的婴儿结肠中的双歧杆菌生长。还可实现潜在病原菌的量的显著减少。已发现给婴儿喂食含有高sn-2棕榈酸酯的含约3g/L至约5g/L或者约0.4g/100kcal至约0.7g/100kcal低聚果糖的婴儿配方乳比喂食婴儿不含低聚果糖的相同配方乳更有益。
与标准婴儿配方乳相比,本发明致使粪便中棕榈酸皂减少,其可使便秘减少和改善肠胃耐受。
本发明的婴儿配方乳含有至少约0.4g低聚果糖/100kcal。在一些实施方案中,其含有约0.4g至约0.9g、约0.4g至约0.7g、约0.4g至约0.5g、约0.7g至约0.8g或者约0.7g至约0.9g低聚果糖/100kcal。低聚果糖具有2-10的聚合度。在一实施方案中,至少90%的低聚果糖具有2-8的聚合度。
最近的婴儿临床研究已表明以约6:约1的比率含有至少一种ω-6脂肪酸和至少一种ω-3脂肪酸的营养配方乳增加红细胞和血浆中的DHA堆积。ω-6脂肪酸与ω-3脂肪酸的约6:1的平衡比率还可提供长期的健康益处,包括保护免于心血管疾病。通过用植物油脂肪源调配本发明将实现所述平衡,所述植物油脂肪源含有ω-6脂肪酸内含物例如大豆油和葵花油,以及ω-3脂肪酸内含物例如油菜籽、卡诺拉油菜(canola)、亚麻籽、奇亚籽(chia)、紫苏(perlla)或核桃。含有5种不同油的独特脂肪混合物将用于获得改良的脂肪混合物。
在一实施方案中,本发明的婴儿配方乳含有约1.8g至约2.2g总蛋白/100kcal,例如约1.8g至约2.1g或者约1.9g至约2.1g蛋白质/100kcal,其中约0.3g至约0.4g/100kcal的蛋白质是α-乳清蛋白。本发明的婴儿配方乳可以是即食的液体形式的或者可以是通过加入一定量的水(致使产生含有约67kcal/100ml的液体)可重构成即食的液体的液体浓缩物或粉末配方乳。本发明的婴儿配方乳包括US或EU的法律中要求的所有成分,其包括但不限于一些维生素、矿物质和必需氨基酸。其还可包含核苷酸例如CMP、UMP、AMP、GMP和IMP、叶黄素、玉米黄素和本领域已知的其他成分。
提供下文的实施例,以阐明本发明的一些实施方案和特征,但是不应该理解为限制本发明的范围。
实施例1
1.对照配方乳
作为即食液体婴儿配方乳,对照配方乳具有670kcal/L。成分如下表所示:
对照配方乳还包括必需氨基酸、矿物质和微量元素、核苷酸,以及通常用于婴儿配方乳的各种任选成分和食品添加剂。
2.高sn-2配方乳
除了9.6重量%的脂肪是sn-2棕榈酸酯之外,所述配方乳与对照配方乳相同。这是采用57%植物油和43%BetapolTMB-55(其中约55%的棕榈酸位于sn-2位)的脂肪完成的。
3.高sn-2+低聚果糖配方乳A
除了其包含3.0g/L(0.4g/100kcal)低聚果糖之外,所述配方乳与高sn-2配方乳相同。
4.高sn-2+低聚果糖配方乳B
除了其包括5.0g/L(0.7g/100kcal)低聚果糖之外,所述配方乳与高sn-2配方乳相同。
5.高sn-2+低聚果糖+ω-6和ω-3配方乳C
除了配方乳C包含约3g/L至约5g/L(约0.75g/100kcal)低聚果糖、以及约4.5g/重构的升(RL)(约0.65g/100kcal)ω-6脂肪酸和约730mg/RL(110mg/100kcal)ω-3脂肪酸之外,所述配方乳与高sn-2配方乳相同。
实施例2
以双盲随机对照设计,进行研究,以比较对照配方乳和三种婴儿配方乳:高sn-2配方乳、高sn-2+低聚果糖配方乳A和高sn-2+低聚果糖配方乳B。未测试配方乳C。人母乳也被引入作为非随机的参照组。将300个配方乳喂养的婴儿随机分成四组(75个/组),并将各组喂食实施例1的不同婴儿配方乳(对照配方乳、高sn-2配方乳、高sn-2+低聚果糖配方乳A、或高sn-2+低聚果糖配方乳B),喂养8周。将另一组75个婴儿喂食人母乳8周。研究开始时,所有婴儿是7-14天龄的健康足月婴儿。
作为结果测量之一,在170个婴儿的亚组中,在基线和第8周访问时采集粪便样品,并利用荧光原位杂交(FISH)方法分析粪便微生物群。已完全证实:FISH是在不培养情况下在临床样品中特异性和快速检测微生物的非常有用的工具。婴儿亚组中粪便微生物群的分析表明:与对照组相比,历经8周,喂食高sn-2棕榈酸酯配方乳(含有("SN2+OF")或者不含有("SN2")加入的低聚果糖)的婴儿具有显著更高的粪便双歧杆菌浓度增加(SN2组,p=0.033;SN2+OF组,p≤0.002),且与母乳(“HM”)喂养的婴儿无显著不同,如图1所示。所述结果表明高sn-2棕榈酸酯配方乳单独对益生双歧杆菌的生长具有刺激作用,引起消化***中双歧杆菌的量增加,更接近母乳喂养婴儿结肠中的天然的量。
为了测量粪便生化组合物,在8周期间采集婴儿粪便样品,并就下列粪便组合物变量进行分析:个体的皂脂肪酸;非皂脂肪酸;总脂肪酸;皂脂质;非皂脂质;矿物质:钙、镁和磷;氮;粪便固体物;和粪便含水量。两个最重要的粪便组合物评价是棕榈酸皂和总脂肪酸皂(统计分析计划中预定)。
在第8周最后访问之前的5天期间,利用提供给父母/法定监护人的套件,在家里收集所有研究婴儿的粪便样品。婴儿使用具有一条Tegaderm带(在该区域婴儿排便以助于粪便保留于尿布中)的尿布。在收集期间,父母舀取新鲜排出的粪便,将样品贮存于琥珀色塑料袋中,在便携秤上称量每个袋子,并将袋子贮存于家用冰箱的冷冻区。
一旦收集了至少30g粪便,研究人员将收集套件冷冻器袋子中的冷冻样品转移至研究诊所,并贮存于-20℃的冷冻箱中。将样品在干冰上冷冻运输至Covance Laboratories,Inc.,麦迪逊,威斯康辛州,USA,在此利用Quinlan等人所用的方法分析样品,以测定总皂脂肪酸;非皂脂肪酸;总脂肪酸;皂脂质;和非皂脂质。使用标准分析操作用于粪便含水量和固体物的测定。根据AOAC国际(AOAC)官方分析方法由ICP发射谱法测定矿物质含量包括钙、磷和镁。通过利用燃烧检测技术的Dumas方法测定氮。
为了测定皂脂肪酸和非皂脂肪酸,将粪便样品解冻,搅拌匀化,并记录湿粪便的重量。然后,将样品冻干,并记录干粪便的重量。将0.5至1.0g粪便的冻干样品转移至提取套管中,并经溶剂回流提取,以得到中性脂质(包含非皂游离脂肪酸)。将套管中剩余的样品用乙酸处理,以释放皂脂肪酸,然后,经第二个溶剂回流步骤将其分离。将内标加入到两种提取物中,并将游离酸吸附到无水碱***换树脂上。然后,从树脂提取游离酸,并利用盐酸和甲醇,将其转化成甲酯。通过气相色谱分析得到的脂肪酸甲酯。所关注的脂肪酸是月桂酸(C12:0)、肉豆蔻酸(C14:0)、棕榈酸(C16:0)、硬脂酸(C18:0)、油酸(C18:1)和亚油酸(C18:2)。所关注的主要脂肪酸是C16:0;因此对于所述测试,将检测限(LOQ)定义为对应于0.05%的最低C16:0校准标准的样品浓度,然后,将其修正为样品重量。与先前用质量控制(QC)样品建立的目标值相比,对于脂肪酸的回收率和变异系数(CVs)的接受标准是与精确度相关的重复分析性能(performance)的+/-30%。对于C16:0的干燥质量控制(QC)水平,重复性相对标准偏差(RSD)值是2.9%-12.6%。总皂脂肪酸计算为所有测量的个体皂脂肪酸的总和。总非皂脂肪酸计算为所有测量的个体非皂脂肪酸的总和。总脂肪酸计算为总非皂脂肪酸加总皂脂肪酸。结果表示为mg/g干粪便重量。
为了测量粪便性质(稠度和频率),在紧靠第4周和第8周的研究访问之前连续3天,父母/法定监护人完成3-天粪便日记,其中他们记录每天的排便次数,以及根据日记说明所附的代表性粪便的标准化图片,将粪便的稠度记录为1=水样,2=水分过多的(runny),3=糊状软的,4=成形的或5=硬的。5种粪便稠度的选项是基于Weaver等人验证的5分评分。
根据图2中所示,喂食无低聚果糖的高sn-2棕榈酸酯配方乳的婴儿比对照组具有显著更不成形的粪便,并且含有高sn-2棕榈酸酯和低聚果糖的配方乳产生甚至更不成形的粪便,接近人乳组的水平。
根据图3中所示,含有和不含低聚果糖的高sn-2棕榈酸酯配方乳与对照配方乳相比都产生显著更低水平的棕榈酸皂,与人乳可比。
文中未例示的本发明的许多变体将呈现给本领域技术人员。本发明不限于文中例示和描述的实施方案,而包括所附权利要求书范围内的所有主题。
Claims (18)
1.婴儿配方乳,其在每100kcal婴儿配方乳中含有约5g至约6g的脂肪,其中约7.5重量%至约12.0重量%的总脂肪具有位于sn-2位的棕榈酸。
2.婴儿配方乳,其在每100kcal婴儿配方乳中含有:
a)约5g至约6g的脂肪,其中至少约7.5重量%的总脂肪具有位于sn-2位的棕榈酸;
b)至少约0.4g低聚果糖;和
c)约1.8g至约2.2g的总蛋白。
3.权利要求2的婴儿配方乳,其中蛋白质包含约0.3g至约0.4gα-乳清蛋白/100kcal。
4.权利要求3的婴儿配方乳,其中总蛋白质是约1.9g至约2.1g/100kcal。
5.权利要求2-4中任何一项的婴儿配方乳,其中约7.5重量%至约12.0重量%的总脂肪具有位于sn-2位的棕榈酸。
6.权利要求5的婴儿配方乳,其中婴儿配方乳包含约0.4g至约0.7g低聚果糖/100kcal。
7.权利要求1或权利要求5的婴儿配方乳,其中约7.8重量%至约11.8重量%的总脂肪具有位于sn-2位的棕榈酸。
8.权利要求2-7中任何一项的婴儿配方乳,其中脂肪中至少约30%的棕榈酸是位于sn-2位。
9.权利要求2的婴儿配方乳,其中:
a)每100kcal,总蛋白质是约1.9g至约2.1g,并包含约0.3gα-乳清蛋白;
b)约7.5%至约12.0%重量的总脂肪具有位于sn-2位的棕榈酸;
c)脂肪中至少约30%的棕榈酸位于sn-2位;和
d)配方乳包含约0.4至约0.5g低聚果糖/100kcal。
10.权利要求2的婴儿配方乳,其中:
a)每100kcal,总蛋白质是约1.9g至约2.1g,并包含约0.3gα-乳清蛋白;
b)约7.5%至约12.0%重量的总脂肪具有位于sn-2位的棕榈酸;
c)脂肪中至少约30%的棕榈酸位于sn-2位;和
d)配方乳包含约0.7至约0.8g低聚果糖/100kcal。
11.权利要求2-10中任何一项的婴儿配方乳,其中脂肪中约35-43%的棕榈酸位于sn-2位。
12.权利要求2-11中任何一项的婴儿配方乳,其中至少约90%的低聚果糖具有2-8的聚合度。
13.用于改善婴儿粪便稠度的方法,其包含向所述婴儿施用权利要求1-12中任何一项的婴儿配方乳。
14.用于减少婴儿粪便中钙皂的量的方法,其包含向所述婴儿施用权利要求1-12中任何一项的婴儿配方乳。
15.增加婴儿粪便中粪便双歧杆菌浓度的方法,其包含向所述婴儿施用权利要求1-12中任何一项的婴儿配方乳。
16.减少婴儿结肠中潜在的病原菌的量的方法,其包含向所述婴儿施用权利要求1-12中任何一项的婴儿配方乳。
17.婴儿配方乳,其在每100kcal婴儿配方乳中含有:
a)约5至约6g的脂肪,其中至少约7.5重量%的总脂肪具有位于sn-2位的棕榈酸;
b)至少约0.4g低聚果糖;
c)约1.8g至约2.2g的总蛋白;和
d)约6:约1比率的至少一种ω-6脂肪酸和至少一种ω-3脂肪酸。
18.婴儿配方乳,其在每100kcal婴儿配方乳中含有:
a)接近约5g至约6g的脂肪,其中至少约7.5重量%的总脂肪由具有位于sn-2位的棕榈酸的甘油三酯构成;
b)任选地,至少约0.4g低聚果糖;
c)约1.8g至约2.2g的总蛋白,任选地包含约0.3g至约0.4g的α-乳清蛋白;和
d)约6:约1比率的至少一种ω-6脂肪酸和至少一种ω-3脂肪酸。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161557950P | 2011-11-10 | 2011-11-10 | |
US61/557,950 | 2011-11-10 | ||
PCT/IB2012/055975 WO2013068879A2 (en) | 2011-11-10 | 2012-10-29 | Infant formula with high sn-2 palmitate and oligofructose |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103929980A true CN103929980A (zh) | 2014-07-16 |
Family
ID=47351884
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280055439.3A Pending CN103929980A (zh) | 2011-11-10 | 2012-10-29 | 含有高sn-2棕榈酸酯和低聚果糖的婴儿配方乳 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20130266684A1 (zh) |
EP (1) | EP2800480A2 (zh) |
CN (1) | CN103929980A (zh) |
AU (1) | AU2012335224B2 (zh) |
BR (1) | BR112014010953A2 (zh) |
CL (1) | CL2014001229A1 (zh) |
MX (1) | MX350870B (zh) |
MY (1) | MY167583A (zh) |
RU (1) | RU2592902C2 (zh) |
TW (1) | TW201325470A (zh) |
WO (1) | WO2013068879A2 (zh) |
ZA (1) | ZA201404233B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105028659A (zh) * | 2015-05-14 | 2015-11-11 | 江南大学 | 一种人乳替代脂组合物 |
CN107105738A (zh) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | 含有水解蛋白质、离子钙和棕榈酸的婴儿营养品 |
CN108471791A (zh) * | 2015-12-18 | 2018-08-31 | 雀巢产品技术援助有限公司 | 用于诱导接近人乳喂养的婴儿的肠道微生物群模式的肠道微生物群模式的含有相对高水平低聚果糖的营养组合物和婴儿配方食品 |
CN112823646A (zh) * | 2019-11-20 | 2021-05-21 | 内蒙古伊利实业集团股份有限公司 | 组合物、食品或药品及其用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016053085A1 (en) | 2014-09-30 | 2016-04-07 | N.V. Nutricia | Composition comprising a uridine source and butyrate producing fibres for preventing gastrointestinal disorders |
WO2016207061A1 (en) * | 2015-06-23 | 2016-12-29 | Nestec S.A. | Nutritional compositions and infant formulas containing oligofructose for reducing the load of pathogenic bacteria in the guts of infants and young children |
US11399559B2 (en) | 2015-07-29 | 2022-08-02 | Abbott Laboratories | Nutritional products having improved lipophilic solubility and bioavailability in an easily mixable form |
ES2879985T3 (es) | 2015-08-04 | 2021-11-23 | Nestle Sa | Composiciones nutritivas y fórmulas infantiles que comprenden Bifidobacterium animalis ssp. lactis y, opcionalmente, una mezcla de oligosacáridos para inducir una microbiota intestinal cercana a la de bebés alimentados por lactancia materna |
CN107847509B (zh) * | 2015-08-04 | 2021-06-01 | 雀巢产品有限公司 | 具有2FL和LNnT的营养组合物 |
US10039805B1 (en) | 2016-02-26 | 2018-08-07 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
US10617700B1 (en) | 2016-02-26 | 2020-04-14 | Michelle Ann Toothman | Vitamin supplement compositions with enhanced bioavailability |
US11122833B1 (en) | 2016-02-26 | 2021-09-21 | Michelle Ann Toothman | Infant formulas having vitamin complexes with enhanced bioavailability |
BR112019001181A2 (pt) | 2016-08-05 | 2019-04-30 | Nestec S.A. | composição de lipídios para uso em bebês e crianças pequenas para promover conforto intestinal e ótima absorção de gordura e cálcio |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
CN111345351A (zh) * | 2020-04-20 | 2020-06-30 | 临夏州燎原乳业有限公司 | 一种新型奶粉以及制造方法 |
WO2022078679A1 (en) | 2020-10-13 | 2022-04-21 | Frieslandcampina Nederland B.V. | Nutritional composition |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1236682C (zh) * | 1999-12-13 | 2006-01-18 | 努特里奇亚有限公司 | 具有改进的蛋白质含量的婴儿配制食品 |
WO2009016632A1 (en) * | 2007-08-01 | 2009-02-05 | Enzymotec Ltd. | Edible fat composition for enhancing bone strength |
US20090121523A1 (en) * | 2007-11-12 | 2009-05-14 | Be Aerospace, Inc. | Convertible passenger seat assembly |
WO2011135564A1 (en) * | 2010-04-26 | 2011-11-03 | Enzymotec Ltd. | Methods and lipid compositions for promoting development of gut flora |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE154826T1 (de) | 1993-05-13 | 1997-07-15 | Loders Croklaan Bv | Verfahren zur herstellung von muttermilch - fettersatzstoffen |
US5827526A (en) * | 1995-07-11 | 1998-10-27 | Abbott Laboratories | Use of indigestible oligosaccharides to prevent gastrointestinal infections and reduce duration of diarrhea in humans |
US6913778B2 (en) * | 2001-12-21 | 2005-07-05 | Wyeth | Infant formula compositions comprising increased amounts of alpha-lactalbumin |
US7651716B2 (en) | 2001-12-21 | 2010-01-26 | Wyeth Llc | Methods for reducing adverse effects of feeding formula to infants |
IL158555A0 (en) | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
KR101368603B1 (ko) | 2005-04-27 | 2014-02-27 | 엔지모테크 리미티드 | 모유 지방 대체물 |
KR101126305B1 (ko) | 2005-09-08 | 2012-03-19 | 로더스 크로클란 비.브이. | 디올레오일 팔미토일 글리세리드 제조 방법 |
EP1928988B1 (en) | 2005-09-08 | 2011-11-09 | Loders Croklaan B.V. | Triglyceride process |
EP1928989B1 (en) | 2005-09-08 | 2011-11-09 | Loders Croklaan B.V. | Process for producing triglycerides |
JP2009533064A (ja) * | 2006-04-11 | 2009-09-17 | マーテック バイオサイエンシーズ コーポレーション | 長鎖多価不飽和脂肪酸を含む食品製品、およびそれらを調製するための方法 |
US20080003329A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
DK2115107T3 (en) | 2007-02-28 | 2018-06-18 | Loders Croklaan Bv | PROCEDURE FOR PREPARING A GLYCERIDE COMPOSITION |
US20090131523A1 (en) * | 2007-10-15 | 2009-05-21 | Enzymotec Ltd. | Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis |
-
2012
- 2012-10-29 MY MYPI2014701195A patent/MY167583A/en unknown
- 2012-10-29 AU AU2012335224A patent/AU2012335224B2/en active Active
- 2012-10-29 CN CN201280055439.3A patent/CN103929980A/zh active Pending
- 2012-10-29 EP EP12799298.0A patent/EP2800480A2/en not_active Withdrawn
- 2012-10-29 BR BR112014010953A patent/BR112014010953A2/pt not_active IP Right Cessation
- 2012-10-29 RU RU2014123509/13A patent/RU2592902C2/ru active
- 2012-10-29 WO PCT/IB2012/055975 patent/WO2013068879A2/en active Application Filing
- 2012-10-29 MX MX2014005628A patent/MX350870B/es active IP Right Grant
- 2012-11-02 US US13/667,765 patent/US20130266684A1/en not_active Abandoned
- 2012-11-09 TW TW101141934A patent/TW201325470A/zh unknown
-
2013
- 2013-10-29 US US14/357,625 patent/US20140323574A1/en not_active Abandoned
-
2014
- 2014-05-09 CL CL2014001229A patent/CL2014001229A1/es unknown
- 2014-06-09 ZA ZA2014/04233A patent/ZA201404233B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1236682C (zh) * | 1999-12-13 | 2006-01-18 | 努特里奇亚有限公司 | 具有改进的蛋白质含量的婴儿配制食品 |
WO2009016632A1 (en) * | 2007-08-01 | 2009-02-05 | Enzymotec Ltd. | Edible fat composition for enhancing bone strength |
US20090121523A1 (en) * | 2007-11-12 | 2009-05-14 | Be Aerospace, Inc. | Convertible passenger seat assembly |
WO2011135564A1 (en) * | 2010-04-26 | 2011-11-03 | Enzymotec Ltd. | Methods and lipid compositions for promoting development of gut flora |
Non-Patent Citations (4)
Title |
---|
KENNEDY K ET AL: "Double-blind,randomized trial of a synthetic triacylglycerol in formula-fed term infants:effects on stool biochemistry,stoolcharacteristics,and bone mineralization", 《THE AMERICAN JOURNEL OF CLINICAL NUTRITION》 * |
MARLOES EJ BONGERS ET AL: "The clinical effect of a new infant formula in term infants with constipation: a double-blind, randomized cross-over trial", 《NUTRITION JOURNAL》 * |
SHEILA M. INNIS ET AL: "Evidence That Palmitic Acid Is Absorbed as sn-2 Monoacylglycerol from Human Milk by Breast-Fed Infants", 《LIPIDS》 * |
YEON-SOOK LEE ET AL: "Effects of sn-2 palmitic acid-fortified vegetable oil and fructooligosaccharide on calcium metabolism in growing rats fed casein based diet", 《NUTRITION RESEARCH AND PRACTICE》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107105738A (zh) * | 2014-12-19 | 2017-08-29 | 雀巢产品技术援助有限公司 | 含有水解蛋白质、离子钙和棕榈酸的婴儿营养品 |
CN105028659A (zh) * | 2015-05-14 | 2015-11-11 | 江南大学 | 一种人乳替代脂组合物 |
CN105028659B (zh) * | 2015-05-14 | 2018-10-30 | 江南大学 | 一种人乳替代脂组合物 |
CN108471791A (zh) * | 2015-12-18 | 2018-08-31 | 雀巢产品技术援助有限公司 | 用于诱导接近人乳喂养的婴儿的肠道微生物群模式的肠道微生物群模式的含有相对高水平低聚果糖的营养组合物和婴儿配方食品 |
CN112823646A (zh) * | 2019-11-20 | 2021-05-21 | 内蒙古伊利实业集团股份有限公司 | 组合物、食品或药品及其用途 |
Also Published As
Publication number | Publication date |
---|---|
RU2014123509A (ru) | 2015-12-20 |
AU2012335224A1 (en) | 2014-04-24 |
WO2013068879A2 (en) | 2013-05-16 |
BR112014010953A2 (pt) | 2017-12-05 |
RU2592902C2 (ru) | 2016-07-27 |
EP2800480A2 (en) | 2014-11-12 |
TW201325470A (zh) | 2013-07-01 |
WO2013068879A3 (en) | 2013-07-11 |
ZA201404233B (en) | 2019-04-24 |
MY167583A (en) | 2018-09-20 |
AU2012335224B2 (en) | 2016-10-13 |
MX350870B (es) | 2017-09-22 |
US20140323574A1 (en) | 2014-10-30 |
MX2014005628A (es) | 2014-10-17 |
US20130266684A1 (en) | 2013-10-10 |
CL2014001229A1 (es) | 2014-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103929980A (zh) | 含有高sn-2棕榈酸酯和低聚果糖的婴儿配方乳 | |
Farfán et al. | The effect of interesterification on the bioavailability of fatty acids in structured lipids | |
Oeffner et al. | Effect of flaxseed supplementation rate and processing on the production, fatty acid profile, and texture of milk, butter, and cheese | |
CN105120688A (zh) | 具有特定比率的低含量MCFAs和相对高含量不饱和脂肪酸的婴儿配方乳,及其在促进婴儿认知功能的健康建立方面的用途 | |
CN103260440A (zh) | 包括含有甘油单酯的新脂肪***的营养型产品 | |
CN103781370A (zh) | 用于调节生命后期食物摄入的婴儿营养物 | |
WO2022156515A1 (zh) | 一种功能食品专用油脂基料油及其制备方法和应用 | |
CN107708447A (zh) | 用于改善胃排空的含有由乳磷脂包裹的植物脂肪的大脂质小球营养品 | |
Oranut et al. | Lipids and fatty acid composition of dried edible red and black ants | |
US20050042256A1 (en) | Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lipid level | |
CN113287659A (zh) | 一种功能结构油及其制备方法和应用 | |
AU2002325344A1 (en) | Lipid blends and food products containing oleic fatty acid and omega-6 fatty acids, designed to increase the intramyocellular lilpid level | |
CN105120687B (zh) | 具有特定比率的低含量中链脂肪酸的婴儿配方乳及其在促进和/或保证婴儿平衡生长方面的用途 | |
Hayat et al. | Fatty acid composition of human milk in Kuwaiti mothers | |
CN101530138A (zh) | 中长链保健膳食油 | |
Korma et al. | A comparative study of lipid composition and powder quality among powdered infant formula with novel functional structured lipids and commercial infant formulas | |
Virginia et al. | Lipids data composition of edible ant eggs Liometopum apiculatum M. escamoles | |
Ahmadpour et al. | Temporal changes in milk fatty acid distribution due to feeding different levels of rolled safflower seeds to lactating Holstein cows | |
CN102438467A (zh) | 阶段1和阶段2婴儿配方乳 | |
Ceballos et al. | Utilization of nitrogen and energy from diets containing protein and fat derived from either goat milk or cow milk | |
WO2020248710A1 (zh) | 一种油脂组合物及其制备方法 | |
Johansson | Effects of genotype, age and feed on the fat components of egg yolk | |
Brzozowska et al. | The use of energy-protein supplement increases performance of high-yielding dairy cows and improves health-promoting properties of milk | |
Stéphanie et al. | In Vivo Evaluation of Omega 3 Fatty Acids Fortified Infant Flours in Relation with the Growth and the Lipid Profile of Rats | |
Salamon et al. | Composition of the mother's milk: II. Fat contents, fatty acid composition. A review. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |
|
RJ01 | Rejection of invention patent application after publication |